Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-426P, formally named "RNA, U6 small nuclear 426, pseudogene," is a processed pseudogene copy of the U6 small nuclear RNA (snRNA) locus[2][3]. While the functional U6 snRNA is an essential, highly conserved non-coding RNA required for mRNA splicing as part of the spliceosome complex[1][3], pseudogenes such as RNU6-426P lack protein-coding potential and are typically non-functional genomic relics generated through mechanisms like retrotransposition[2]. These pseudogenes are characterized by sequence similarity to the parent U6 snRNA gene but generally lack regulatory elements and/or are subject to disablement mutations[2]. There is no evidence or scientific consensus designating RNU6-426P as a therapeutic target, nor does it have established roles in disease, drug interactions, or biomarker utility. The presence of such pseudogenes in the genome reflects the evolutionary dynamics of transposable elements and small RNA gene families but does not impart functional biological activity[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 426, pseudogene (RNU6-426P).